Fiscal year 2023 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses DCPH in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named DCPH in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Steven Hoerter | $738,200 | $0 | $1,935,000 | $2,837,100 | $487,212 | $0 | $13,200 | $6,010,712 |
| President and Chief Executive Officer | ||||||||
| Dashyant Dhanak | 195,455 | 0 | 1,890,878 | 673,874 | 297,000 | 0 | 6,000 | 3,063,207 |
| Executive Vice President, Chief Scientific Officer | ||||||||
| Matthew Sherman | 573,500 | 0 | 510,468 | 747,860 | 283,883 | 0 | 13,200 | 2,128,911 |
| Executive Vice President, Chief Medical Officer | ||||||||
| Thomas Kelly | 507,875 | 0 | 510,468 | 747,860 | 251,398 | 0 | 13,200 | 2,030,801 |
| Executive Vice President, Chief Financial Officer and Treasurer | ||||||||
| Daniel Flynn | 501,970 | 0 | 510,468 | 747,860 | 0 | 0 | 239,087 | 1,999,385 |
| Founder and Former Executive Vice President, Chief Scientific Officer | ||||||||
| Daniel Martin | 496,065 | 0 | 345,235 | 506,139 | 218,269 | 0 | 13,200 | 1,578,908 |
| Senior Vice President, Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Steven Hoerter | $6,010,712 | $3,554,485 | $9,414,654 | +2,456,227 |
| Dashyant Dhanak | 3,063,207 | — | — | — |
| Matthew Sherman | 2,128,911 | 1,491,982 | 3,462,594 | +636,929 |
| Thomas Kelly | 2,030,801 | 1,405,209 | 3,380,862 | +625,592 |
| Daniel Flynn | 1,999,385 | 1,385,537 | 3,382,347 | +613,848 |
| Daniel Martin | 1,578,908 | 1,128,992 | 2,665,893 | +449,916 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Thomas Kelly | PSU | 2023-02-15 | — | 24,732 | — | 16,488 | $510,468 |
| Dashyant Dhanak | — | 2023-09-15 | — | — | 140,900 | — | 1,890,878 |
| Daniel Flynn | OPTION | 2023-02-15 | — | — | 65,900 | — | 747,860 |
| Thomas Kelly | OPTION | 2023-02-15 | — | — | 65,900 | — | 747,860 |
| Steven Hoerter | — | 2023-02-15 | — | — | 187,500 | — | 1,935,000 |
| Matthew Sherman | PSU | 2023-02-15 | — | 24,732 | — | 16,488 | 510,468 |
| Steven Hoerter | OPTION | 2023-02-15 | — | — | 250,000 | — | 2,837,100 |
| Dashyant Dhanak | OPTION | 2023-09-15 | — | — | 65,900 | — | 673,874 |
| Daniel C. Martin | OPTION | 2023-02-15 | — | — | 44,600 | — | 506,139 |
| Matthew Sherman | OPTION | 2023-02-15 | — | — | 65,900 | — | 747,860 |
| Daniel C. Martin | PSU | 2023-02-15 | — | 16,727 | — | 11,151 | 345,235 |
| Daniel Flynn | PSU | 2023-02-15 | — | 24,732 | — | 16,488 | 510,468 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Thomas Kelly | $0 | $510,468 | $747,860 | 40.6% |
| Dashyant Dhanak | 0 | 0 | 673,874 | 0.0% |
| Daniel Flynn | 0 | 510,468 | 747,860 | 40.6% |
| Steven Hoerter | 0 | 0 | 2,837,100 | 0.0% |
| Matthew Sherman | 0 | 510,468 | 747,860 | 40.6% |
| Daniel C. Martin | 0 | 345,235 | 506,139 | 40.6% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Matthew Sherman | RSU | 13,665 | — | $220,416 |
| Dashyant Dhanak | RSU | 140,900 | — | 2,272,717 |
| Steven Hoerter | RSU | 62,500 | — | 1,008,125 |
| Martin | RSU | 5,575 | — | 89,925 |
| Martin | RSU | 4,150 | — | 66,940 |
| Steven Hoerter | Option | 61,250 | 47.79 | — |
| Steven Hoerter | Option | 197,917 | 15.48 | — |
| Martin | Option | 28,472 | 8.27 | — |
| Martin | Option | 35,308 | 15.48 | — |
| Daniel Flynn | RSU | 13,665 | — | 220,416 |
| Matthew Sherman | RSU | 16,488 | — | 265,951 |
| Martin | RSU | 1,760 | — | 28,389 |
| Daniel Flynn | Option | 52,171 | 15.48 | — |
| Steven Hoerter | Option | 216,146 | 8.27 | — |
| Thomas Kelly | RSU | 13,665 | — | 220,416 |
| Thomas Kelly | Option | 14,554 | 47.79 | — |
| Matthew Sherman | Option | 42,708 | 8.27 | — |
| Thomas Kelly | RSU | 5,550 | — | 89,522 |
| Daniel Flynn | Option | 42,708 | 8.27 | — |
| Matthew Sherman | RSU | 5,550 | — | 89,522 |
| Thomas Kelly | RSU | 8,244 | — | 132,976 |
| Matthew Sherman | Option | 52,171 | 15.48 | — |
| Daniel Flynn | RSU | 5,550 | — | 89,522 |
| Daniel Flynn | RSU | 16,488 | — | 265,951 |
| Matthew Sherman | RSU | 440 | — | 7,097 |
| Matthew Sherman | RSU | 8,244 | — | 132,976 |
| Thomas Kelly | Option | 42,708 | 8.27 | — |
| Daniel Flynn | RSU | 1,760 | — | 28,389 |
| Thomas Kelly | Option | 52,171 | 15.48 | — |
| Martin | Option | 1,758 | 54.87 | — |
| Thomas Kelly | Option | 1,758 | 54.87 | — |
| Matthew Sherman | Option | 14,554 | 47.79 | — |
| Thomas Kelly | RSU | 16,488 | — | 265,951 |
| Thomas Kelly | RSU | 1,760 | — | 28,389 |
| Daniel Flynn | RSU | 8,244 | — | 132,976 |
| Daniel Flynn | Option | 14,554 | 47.79 | — |
| Daniel Flynn | Option | 1,758 | 54.87 | — |
| Martin | RSU | 11,151 | — | 179,866 |
| Martin | RSU | 9,110 | — | 146,944 |
| Steven Hoerter | Option | 7,500 | 54.87 | — |
| Matthew Sherman | Option | 438 | 54.87 | — |
| Dashyant Dhanak | Option | 65,900 | 13.42 | — |
| Martin | Option | 10,879 | 47.79 | — |
Our executive compensation program is guided by our overarching philosophy of paying for demonstrable performance. Consistent with this philosophy, we have designed our executive compensation program to achieve the following primary goals: attract, motivate, and retain top-performing executives; establish compensation opportunities that are competitive and reward performance; and align the interests of our executive team members with those of our stockholders to drive the creation of sustainable long-term value.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| James A. Bristol, Ph.DIndependent · Compensation (Chair) · Nominating/Governance · Science and Technology | $86,174 | $0 | $328,593 | — | $0 | $414,767 |
| Ron SquarerIndependent · Board Chair · Audit | 74,702 | 0 | 328,593 | — | 0 | 403,295 |
| Patricia L. AllenIndependent · Audit (Chair) | 69,960 | 0 | 328,593 | — | 0 | 398,553 |
| Edward J. Benz Jr., M.DIndependent · Nominating/Governance (Chair) · Science and Technology | 67,500 | 0 | 328,593 | — | 0 | 396,093 |
| Susan L. Kelley, M.DIndependent · Compensation · Science and Technology (Chair) | 67,460 | 0 | 328,593 | — | 0 | 396,053 |
| John R. MartinIndependent · Audit | 60,000 | 0 | 328,593 | — | 0 | 388,593 |
| Dennis L. WalshIndependent · Compensation | 57,460 | 0 | 328,593 | — | 0 | 386,053 |
| Frank S. FriedmanIndependent · Nominating/Governance | 53,710 | 0 | 328,593 | — | 0 | 382,303 |
| Steven L. HoerterEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $536,966 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $536,966 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Deciphera Pharmaceuticals names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Deciphera Pharmaceuticals.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Scholar Rock Holding Corporation | 2025 | David Hallal | $637,500 | $22,518,500 | $7,624,988 | $452,293 | $33,300,927 |
| 2 | Cogent Biosciences | 2025 | Andrew Robbins | 724,554 | 12,993,250 | 13,447,680 | 561,600 | 27,762,684 |
| 3 | SpringWorks Therapeutics | 2024 | Saqib Islam | 760,000 | 7,899,760 | 6,689,100 | 798,000 | 16,153,317 |
| 4 | BridgeBio Pharma | 2025 | Neil Kumar | 1,044,000 | 10,606,275 | 1,874,992 | 0 | 14,944,585 |
| 5 | Arcus Biosciences | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 6 | Amicus Therapeutics | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 7 | Syndax Pharmaceuticals | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 8 | Arvinas | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 9 | Allogene Therapeutics | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 10 | Deciphera Pharmaceuticals | 2023 | Steven Hoerter | 738,200 | 1,935,000 | 2,837,100 | 487,212 | 6,010,712 |
| 11 | NGM Biopharmaceuticals | 2022 | David Woodhouse | 610,000 | 0 | 5,072,750 | 250,000 | 5,933,500 |
| 12 | Replimune Group | 2026 | Sushil Patel | 700,000 | 3,376,003 | 1,448,325 | 315,000 | 5,845,982 |
| 13 | Agios Pharmaceuticals | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 14 | Y-mAbs Therapeutics | 2024 | Michael Rossi | 705,600 | 1,170,732 | 2,288,662 | 392,596 | 4,557,590 |
| 15 | Coherus BioSciences | 2025 | Dennis Lanfear | 1,026,545 | 0 | 828,130 | 869,295 | 2,736,874 |
| 16 | Karyopharm Therapeutics | 2025 | Richard Paulson | 770,000 | 838,996 | 241,544 | 350,350 | 2,320,902 |
| 17 | Seres Therapeutics | 2025 | Eric Shaff | 408,333 | 0 | 1,338,870 | 0 | 1,775,549 |
| 18 | Mersana Therapeutics | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| — | EQRx | — | — | — | — | — | — | not in coverage universe |
| — | Mirati Therapeutics | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Deciphera Pharmaceuticals | 110% | Options 50 · PSU 50 | No | Pearl Meyer & Partners, LLC |
| Agios Pharmaceuticals | 100% | Options 40 · PSU 40 · RSU 20 | No | Aon |
| Allogene Therapeutics | 85% | Options 55 · RSU 25 · PSU 20 | No | Compensia |
| Amicus Therapeutics | 108% | Options 33 · RSU 33 · PSU 33 | Yes — TSR Goal | Pay Governance |
| Arcus Biosciences | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Arvinas | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| BridgeBio Pharma | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Cogent Biosciences | 135% | not disclosed | No | Compensia |
| Coherus BioSciences | not disclosed | Options 100 | not disclosed | Aon |
| EQRx | not disclosed | not disclosed | not disclosed | not disclosed |
| Karyopharm Therapeutics | 90% | not disclosed | Yes — Relative TSR | Alpine Rewards, LLC (through September 2025); Willis Towers Watson (beginning August 2025) |
| Mersana Therapeutics | 85% | Options 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| Mirati Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| NGM Biopharmaceuticals | 75% | Options 100 | not disclosed | Aon plc (Human Capital Solutions practice) |
| Replimune Group | not disclosed | not disclosed | No | Pearl Meyer |
| Scholar Rock Holding Corporation | not disclosed | not disclosed | No | Pay Governance |
| Seres Therapeutics | not disclosed | Options 100 | not disclosed | Alpine Rewards, LLC |
| SpringWorks Therapeutics | 140% | not disclosed | Yes — Relative Total Shareholder Return (TSR) | Aon plc (Human Capital Solutions practice) |
| Syndax Pharmaceuticals | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
| Y-mAbs Therapeutics | 85.6% | PSU 34 · Options 33 · RSU 33 | No | Aon's Human Capital Solutions practice (division of Aon plc) |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Steven Hoerter | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Summary Compensation Table – 2023, 2022, and 2021 Fiscal Years”. As printed: 6,010,712. Filing ↗machine: span 605886–605895 |
| 2 | Section 01, Dashyant Dhanak | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Summary Compensation Table – 2023, 2022, and 2021 Fiscal Years”. As printed: 3,063,207. Filing ↗machine: span 641248–641257 |
| 3 | Section 01, Matthew Sherman | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Summary Compensation Table – 2023, 2022, and 2021 Fiscal Years”. As printed: 2,128,911. Filing ↗machine: span 623551–623560 |
| 4 | Section 01, Thomas Kelly | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Summary Compensation Table – 2023, 2022, and 2021 Fiscal Years”. As printed: 2,030,801. Filing ↗machine: span 614909–614918 |
| 5 | Section 01, Daniel Flynn | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Summary Compensation Table – 2023, 2022, and 2021 Fiscal Years”. As printed: 1,999,385. Filing ↗machine: span 632591–632600 |
| 6 | Section 01, Daniel Martin | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Summary Compensation Table – 2023, 2022, and 2021 Fiscal Years”. As printed: 1,578,908. Filing ↗machine: span 645468–645477 |
| 7 | Section 03, Thomas Kelly PSU | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t23 · r8 · c17 · span 674569–674576 |
| 8 | Section 03, Dashyant Dhanak | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t23 · r17 · c17 · span 692614–692623 |
| 9 | Section 03, Daniel Flynn OPTION | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t23 · r13 · c18 · span 684513–684520 |
| 10 | Section 03, Thomas Kelly OPTION | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t23 · r7 · c18 · span 672642–672649 |
| 11 | Section 03, Steven Hoerter | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t23 · r5 · c17 · span 669266–669275 |
| 12 | Section 03, Matthew Sherman PSU | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t23 · r11 · c17 · span 681143–681150 |
| 13 | Section 03, Steven Hoerter OPTION | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t23 · r4 · c18 · span 666910–666919 |
| 14 | Section 03, Dashyant Dhanak OPTION | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t23 · r16 · c18 · span 690671–690678 |
| 15 | Section 03, Daniel C. Martin OPTION | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t23 · r19 · c18 · span 695980–695987 |
| 16 | Section 03, Matthew Sherman OPTION | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t23 · r10 · c18 · span 678791–678798 |
| 17 | Section 03, Daniel C. Martin PSU | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t23 · r20 · c17 · span 697907–697914 |
| 18 | Section 03, Daniel Flynn PSU | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t23 · r14 · c17 · span 686440–686447 |
| 19 | Section 08, James A. Bristol, Ph.D | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Director Compensation”. As printed: 414,767. Filing ↗machine: t11 · r4 · c8 · span 281827–281834 |
| 20 | Section 08, Ron Squarer | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Director Compensation”. As printed: 403,295. Filing ↗machine: t11 · r8 · c8 · span 289391–289398 |
| 21 | Section 08, Patricia L. Allen | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Director Compensation”. As printed: 398,553. Filing ↗machine: t11 · r2 · c8 · span 278398–278405 |
| 22 | Section 08, Edward J. Benz Jr., M.D | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Director Compensation”. As printed: 396,093. Filing ↗machine: t11 · r3 · c8 · span 280126–280133 |
| 23 | Section 08, Susan L. Kelley, M.D | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Director Compensation”. As printed: 396,053. Filing ↗machine: t11 · r6 · c8 · span 285747–285754 |
| 24 | Section 08, John R. Martin | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Director Compensation”. As printed: 388,593. Filing ↗machine: t11 · r7 · c8 · span 287439–287446 |
| 25 | Section 08, Dennis L. Walsh | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Director Compensation”. As printed: 386,053. Filing ↗machine: t11 · r9 · c8 · span 291347–291354 |
| 26 | Section 08, Frank S. Friedman | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Director Compensation”. As printed: 382,303. Filing ↗machine: t11 · r5 · c8 · span 283785–283792 |
| 27 | Section 08, Steven L. Hoerter | DEF 14A | 2024-04-25 | 0001654151-24-000012 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 28 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 29 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 30 | Section 09b board cost (computed) | Computed | — | computed | Cash 536,966 + equity 0 + all other 0 = 536,966, summed across the director compensation table rows.machine: formula: Σ = 536,966 |
| 31 | Scholar Rock Holding Corporation, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001104659-26-046917 | CEO total compensation as printed in Scholar Rock Holding Corporation's own proxy. As printed: 33,300,927. Filing ↗machine: r1 · c47 · span 363867–363877 |
| 32 | Cogent Biosciences, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173834 | CEO total compensation as printed in Cogent Biosciences's own proxy. As printed: 27,762,684. Filing ↗machine: r2 · c39 · span 369353–369363 |
| 33 | SpringWorks Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-04 | 0001104659-25-032187 | CEO total compensation as printed in SpringWorks Therapeutics's own proxy. As printed: 16,153,317. Filing ↗machine: t23 · r1 · c44 · span 623184–623194 |
| 34 | BridgeBio Pharma, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016723 | CEO total compensation as printed in BridgeBio Pharma's own proxy. As printed: 14,944,585. Filing ↗machine: r2 · c21 · span 527521–527531 |
| 35 | Arcus Biosciences, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001724521-26-000025 | CEO total compensation as printed in Arcus Biosciences's own proxy. As printed: 9,656,813. Filing ↗machine: r2 · c48 · span 403740–403749 |
| 36 | Amicus Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Therapeutics's own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736127–736137 |
| 37 | Syndax Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-197859 | CEO total compensation as printed in Syndax Pharmaceuticals's own proxy. As printed: 7,089,213. Filing ↗machine: span 936322–936331 |
| 38 | Arvinas, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028156 | CEO total compensation as printed in Arvinas's own proxy. As printed: 6,534,127. Filing ↗machine: t20 · r3 · c22 · span 471921–471930 |
| 39 | Allogene Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001628280-26-028948 | CEO total compensation as printed in Allogene Therapeutics's own proxy. As printed: 6,136,093. Filing ↗machine: r2 · c54 · span 451014–451023 |
| 40 | Deciphera Pharmaceuticals (subject), Section 10b CEO total | DEF 14A | 2024-04-25 | 0001654151-24-000012 | CEO total compensation as printed in Deciphera Pharmaceuticals's own proxy. As printed: 6,010,712. Filing ↗machine: span 605886–605895 |
| 41 | NGM Biopharmaceuticals, Section 10b CEO total | DEF 14A | 2023-03-29 | 0001628280-23-009712 | CEO total compensation as printed in NGM Biopharmaceuticals's own proxy. As printed: 5,933,500. Filing ↗machine: r2 · c42 · span 406619–406628 |
| 42 | Replimune Group, Section 10b CEO total | DEF 14A | 2026-07-29 | 0001104659-26-087650 | CEO total compensation as printed in Replimune Group's own proxy. As printed: 5,845,982. Filing ↗machine: r1 · c41 · span 430765–430774 |
| 43 | Agios Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177086 | CEO total compensation as printed in Agios Pharmaceuticals's own proxy. As printed: 5,370,389. Filing ↗machine: r2 · c31 · span 613185–613194 |
| 44 | Y-mAbs Therapeutics, Section 10b CEO total | DEF 14A | 2025-05-30 | 0001558370-25-008299 | CEO total compensation as printed in Y-mAbs Therapeutics's own proxy. As printed: 4,557,590. Filing ↗machine: t100 · r5 · c23 · span 597595–597604 |
| 45 | Coherus BioSciences, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045251 | CEO total compensation as printed in Coherus BioSciences's own proxy. As printed: 2,736,874. Filing ↗machine: t112 · r5 · c14 · span 540087–540096 |
| 46 | Karyopharm Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-13 | 0001503802-26-000023 | CEO total compensation as printed in Karyopharm Therapeutics's own proxy. As printed: 2,320,902. Filing ↗machine: r2 · c29 · span 1192339–1192348 |
| 47 | Seres Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001193125-26-182036 | CEO total compensation as printed in Seres Therapeutics's own proxy. As printed: 1,775,549. Filing ↗machine: r2 · c29 · span 928055–928064 |
| 48 | Mersana Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-29 | 0001104659-25-040448 | CEO total compensation as printed in Mersana Therapeutics's own proxy. As printed: 1,613,754. Filing ↗machine: t16 · r1 · c41 · span 608188–608197 |
| 49 | Section 10a, Seres Therapeutics reciprocity | DEF 14A | — | 0001193125-26-182036 | Seres Therapeutics's most recent proxy was read; its disclosed peer group does not include Deciphera Pharmaceuticals. Filing ↗ |
| 50 | Section 10a, Syndax Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-197859 | Syndax Pharmaceuticals names Deciphera Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 51 | Section 10a, Y-mAbs Therapeutics reciprocity | DEF 14A | — | 0001558370-25-008299 | Y-mAbs Therapeutics names Deciphera Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 52 | Section 10a, Cogent Biosciences reciprocity | DEF 14A | — | 0001193125-26-173834 | Cogent Biosciences's most recent proxy was read; its disclosed peer group does not include Deciphera Pharmaceuticals. Filing ↗ |
| 53 | Section 10a, SpringWorks Therapeutics reciprocity | DEF 14A | — | 0001104659-25-032187 | SpringWorks Therapeutics names Deciphera Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 54 | Section 10a, BridgeBio Pharma reciprocity | DEF 14A | — | 0001140361-26-016723 | BridgeBio Pharma's most recent proxy was read; its disclosed peer group does not include Deciphera Pharmaceuticals. Filing ↗ |
| 55 | Section 10a, Coherus BioSciences reciprocity | DEF 14A | — | 0001104659-26-045251 | Coherus BioSciences names Deciphera Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 56 | Section 10a, Amicus Therapeutics reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Therapeutics's most recent proxy was read; its disclosed peer group does not include Deciphera Pharmaceuticals. Filing ↗ |
| 57 | Section 10a, Arvinas reciprocity | DEF 14A | — | 0001628280-26-028156 | Arvinas's most recent proxy was read; its disclosed peer group does not include Deciphera Pharmaceuticals. Filing ↗ |
| 58 | Section 10a, NGM Biopharmaceuticals reciprocity | DEF 14A | — | 0001628280-23-009712 | NGM Biopharmaceuticals's most recent proxy was read; its disclosed peer group does not include Deciphera Pharmaceuticals. Filing ↗ |
| 59 | Section 10a, Allogene Therapeutics reciprocity | DEF 14A | — | 0001628280-26-028948 | Allogene Therapeutics's most recent proxy was read; its disclosed peer group does not include Deciphera Pharmaceuticals. Filing ↗ |
| 60 | Section 10a, Agios Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-177086 | Agios Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Deciphera Pharmaceuticals. Filing ↗ |
| 61 | Section 10a, Scholar Rock Holding Corporation reciprocity | DEF 14A | — | 0001104659-26-046917 | Scholar Rock Holding Corporation's most recent proxy was read; its disclosed peer group does not include Deciphera Pharmaceuticals. Filing ↗ |
| 62 | Section 10a, Mersana Therapeutics reciprocity | DEF 14A | — | 0001104659-25-040448 | Mersana Therapeutics's most recent proxy was read; its disclosed peer group does not include Deciphera Pharmaceuticals. Filing ↗ |